From Proof to Practice – Treating Hypertension With uRDN
Watch this broadcast on-demand to learn about uRDN clinical data and how to implement this therapy in the real world to treat patients with hypertension. We join Prof Joachim Weil (Sana Hospital Lübeck, DE) who will be moderating this session, alongside Dr Joost Daemen (Erasmus University Hospital, NL) and Prof Atul Pathak (Princess Grace Hospital, FR) who will be discussing the latest clinical results and who should be treated with uRDN.
Ultrasound Renal Denervation (uRDN) is an innovative therapy option for the treatment of uncontrolled hypertension. uRDN therapy is delivered in a minimally invasive procedure that may lower high blood pressure by treating overactive renal nerves with ultrasound energy.
*The Paradise™ System is Limited to Investigational Use Only in the United States. Approved for distribution in CE mark countries only.
This broadcast was supported by Recor Medical
Ultrasound RDN – Reviewing the Latest Clinical Results
Prof Atul Pathak
Who Should Be Treated With uRDN
Dr Joost Daemen
How to Build the Interventional HTN Therapy / Practice
Prof Joachim Weil
- Review the latest clinical evidence on Ultrasound RDN for the treatment of hypertension
- Learn latest consensus/guidelines on patient selection for treatment with RDN
- Understand RDN centre criteria to build interventional hypertension therapy
- Interventional Cardiologist
- Hypertension experts
- Interventional Radiologist
Dr Atul Pathak is a Pharmacologist and Cardiologist. He is leading a clinical research team focusing on cardiovascular pathophysiology and clinical pharmacology and is affiliated to INSERM (National Institute of Medical Research).
Dr Pathak has been awarded by the ESC (Young Investigator Award), by the British Pharmacological Society and the French Society of Cardiology. He is also member of the French Association of Pharmacologists, the French Society of Hypertension and Cardiology, the American Society for Heart Failure. He is elected President of the Cardiovascular Pharmacology Working Group of the French Society of Cardiology. He has both academic and institutional commitments, among them participation at advisory board at AFSSAPS (French FDA) and HAS for the review of clinical trials protocol, assessment of benefit /risk ratio of drugs (marketed or under development) and medico-economic issues (regarding lipid or blood pressure lowering drugs).
Dr Joost Daemen, MD, PhD obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam.
Joost is actively involved in several drug-eluting stent trials and is Principal Investigator of 4 trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Joost is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.
Prof Joachim Weil is the Head of the Medical Department II - Cardiology and Angiology of the Sana Hospitals Lübeck. As a modern competence center, the Department of Cardiology and Angiology offers highly specialized medical services in addition to cardiological care. In addition, Sana Hospitals Lübeck cooperates closely with the University Hospital of Schleswig-Holstein.
Professor Joachim Weil is one of Germany's renowned experts in the treatment of cardiovascular diseases and has received the Focus Award "TOP Physician - Hypertension" several times. He has longstanding experience especially in the field of renal denervation and is head of the clinical research group.